Sophiris Bio, a biotech focused on developing products for the treatment of urological diseases, announced terms for its IPO on Friday. The La Jolla, CA-based company plans to raise $65 million by offering 5.0 million shares at $13 per share. At a $13 offer price, Sophiris Bio would command a market value of $104 million. Sophiris Bio, which was founded in 2002, plans to list on the NASDAQ under the symbol SPHS. Sophiris Bio initially filed confidentially on December 7, 2012. Citi and Leerink Swann are the joint bookrunners on the deal.
